EGFR and non-small cell lung carcinoma: The largest available dataset based on a prospective study is an unplanned retrospective analysis from the phase III CTONG 0901 trial, which compared the efficacy of erlotinib to gefitinib in advanced NSCLC harboring EGFR exon 19 or 21 mutations, measured by NGS.